Asian Conference on Tumor Ablation guidelines for renal cell carcinoma

Byung Kwan Park1, Shu-Huei Shen2, Masashi Fujimori3, Yi Wang4

1Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 2Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan, 3Department of Radiology, Mie University School of Medicine, Mie Prefecture, Japan, 4Department of Urology, Peking University Wujieping Urology Center, Peking University Shougang Hospital, Beijing, China

Thermal ablation has been established as an alternative treatment for renal cell carcinoma (RCC) in patients who are poor candidates for surgery. However, while American and European guidelines have been established for American and European patients, respectively, no ablation guidelines for Asian patients with RCCs have been established many years after the Asian Conference on Tumor Ablation (ACTA) had been held. Given that Western guidelines are difficult to apply to Asian patients due to differences in body habitus, economic status, and insurance systems, the current review sought to establish the first version of the ACTA guidelines for treating a RCC with thermal ablation.

Keywords: Carcinoma, renal cell; Cryosurgery; Microwaves; Radiofrequency ablation

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Incidental renal cell carcinoma (RCC) has been increasingly detected during ultrasound (US), computed tomography (CT), or magnetic resonance imaging (MRI) for unrelated reasons [1-3]. Moreover, estimates have shown that registered incidences of RCC across China has increased yearly from 1998 to 2008, with the average annual growth rate being 7.89% and males having higher incidences rates than females (8.13% vs. 7.51%, respectively) [4]. According to the cancer registration data of the National Central Cancer Registry of China, approximately 68,300 new RCC cases occurred nationally in 2014, with the crude incidence and mortality rates being 4.99/100,000 and 1.87/100,000, respectively [5].

Although partial or radical nephrectomy has remained the treatment of choice for small RCC, thermal ablation has been considered a plausible alternative treatment given the recent advancements in ablation techniques [6,7]. Since 2000, thermal ablation techniques, such as radiofrequency ablation (RFA), cryoablation, and microwave ablation (MWA), have become increasingly available in clinical practice and utilized as the main treatment modalities. These minimally invasive treatments have been established as excellent alternatives to surgery among American [8] or European [9] patients. However, ablation guidelines for Asian patients with RCC have yet to be established despite the Asian Conference on Tumor Ablation (ACTA) having been held for quite some time. Therefore, the ACTA committee had been tasked to create guidelines for ablation. The current review aimed to establish the first version of the ACTA guidelines for treating RCC with thermal ablation.


**METHODS**

These guidelines did not need approval of Institutional review board because it is a review article. Thus, written informed consent was not necessary. Three radiologists (BKP, SHS, MF) and one urologist (YW), who came from Asian countries including Korea, Taiwan, Japan, and China, were the key members in the guideline ACTA committee for renal tumor ablation. They developed the key questions and discussed each guideline. Renal tumor ablation guidelines were built up after they reviewed many investigations including randomized controlled studies, meta-analyses, case-control studies, expert opinions, and case series. Finally, each guideline was built by means of consensus agreement after it was discussed based on literatures review and our experiences. The levels of recommendations were graded as A, B, C, and D according to the guidelines [10]. The key questions were described in the Table 1 [10]. Recommendation A is defined when there is a clear rationale with multiple randomized controlled trials that can be generalized because they have sufficient test or meta-analysis results supports a recommendation [10]. Recommendation B is defined when there is a reliable basis with reasonable grounds supporting this through well-performed cohort studies or patient – control group studies [10]. Recommendation C is defined when there is a possible basis with relevant grounds which are seen through randomized clinical studies or case reports and observational studies carried out in a small institution, despite their inherent unreliability [10]. Recommendation D is defined as expert opinions in which there is no basis to support the recommendation, but they are supported by expert opinion or expert clinical experience [10].

1. **Pre-ablation considerations**

   **1) Treatment indications**

   The American Urological Association (AUA) and European Association of Urology (EAU) recommend partial or radical nephrectomy as the treatment of choice and consider thermal ablation a secondary treatment option for patients with RCC [6,7], mainly due to the lacking of strong evidence in support of replacing partial nephrectomy. Although several investigations [11-17], have shown that thermal ablation has potential as a primary treatment for RCC, such studies were not randomized controlled trials. Therefore, evidence-based studies demonstrating that thermal ablation is not inferior to nephrectomy in terms of oncologic outcomes are needed.

   Despite the lack of evidence, the AUA and EAU recommend ablation therapy as the primary treatment for patients who are poor surgical candidates due to increased risk for postoperative morbidity [6,7]. Such clinical characteristics consist of impaired cardiopulmonary function, chronic liver disease, chronic kidney disease, prolonged bleeding time, deficient coagulation factors, and other severe co-existing morbidities. Moreover, studies have shown that ablation therapy can be a good alternative for treating hereditary RCC [18,19], single kidney RCC [12,20,21], central RCC [15,22,23], and recurrent RCCs [24-26]. While no absolute contraindications

| Table 1. Key questions and recommendation levels in renal tumor ablation guidelines |
|-----------------------------------------------|-----------------------------------------------|
| **Key question**                              | **Recommended guideline**                      | **Recommendation level** |
| What are indications in treating an RCC?      | Patients with high risk of post-operative morbidity | B                      |
| What is the role of pre-ablation imaging?     | Making a treatment planning                     | B                      |
| What are patients’ preparations prior to ablation therapy? | NPO and stable laboratory findings             | B                      |
| What type of anesthesia is recommended in each ablation? | Conscious sedation, monitored anesthesia care, or general anesthesia | B                      |
| What are prevention methods to avoid thermal damage? | Position change, leveraging applicator, or hydrodissection | B                      |
| Is renal mass biopsy necessary prior to thermal ablation? | Biopsy is mandatory to avoid a benign tumor. | B                      |
| What ablation modality is chosen in treating an RCC? | Small RCC (<3 cm) can be treated with all types of ablations. Cryoablation and microwave is recommended to treat large RCC (≥3 cm). | C                      |
| What imaging modality is chosen in guiding ablations? | CT is the best modality, but US can be used for treating exophytic RCC. | B                      |
| Is thermal ablation useful in treating a cystic renal mass? | Thermal ablation is useful for treating cystic renal mass. | B                      |
| What are the protocols, complications, and outcomes? | See the details in the section of thermal ablation modalities. | B                      |
| How or when should patients be followed?      | Every 6 months within 2 years and once a year until 5 years | B                      |
| How does thermal ablation influence renal function? | Many tumor factors involved in affecting renal function change. | B                      |

RCC, renal cell carcinoma; NPO, nil per os.
exist for thermal ablation, relative contraindications include fever, severe coagulopathy, and severe bleeding tendencies. However, thermal ablation can be performed granted that these conditions are addressed. Prior to thermal ablation, fever should be assessed and controlled. Moreover, the platelet count should not fall below 50,000, while the internalized normalized ratio should exceed 1.5 [27].

2) Pre-ablation imaging for planning
Pre-ablation imaging is important for establishing treatment plans given that it allows for lesion detection and characterization, lesion localization, lesion approach determination, and prevention of complications [8,9]. Considering that pre-ablation imaging increases medical cost and radiation exposure [28,29], carefully balancing the effectiveness, and hazards of pre-ablation imaging when managing patients with RCC is imperative. Numerous interventional radiologists prefer using CT guidance for thermal ablation given its shorter scan time, lower medical cost, fewer imaging artifacts, and increased availability [8,9,30]. However, MRI should be considered in pediatric or pregnant patients, as well as those sensitive to iodine contrast material. While US is generally useful in detecting or characterizing renal mass, this modality cannot replace CT or MRI given its inability to guide pre-ablation planning as stated earlier.

3) Patient preparations
Pre-ablation CT or MR images should be carefully assessed to determine the appropriate approach for RCC, type of thermal ablation technique, patient positioning during ablation procedures, and prevention of thermal injury to neighboring organs [31].

Patients should fast more than 6 hours before ablation therapy given that risk for aspiration when non-fasted patients vomit during ablation procedures [15,32]. Furthermore, fasting is necessary considering that interventional oncocologists need to prepare for emergency arterial embolization, percutaneous nephrostomy, or ureter catheterization when intractable bleeding or hematuria, irreversible ureter obstruction, or uncontrolled urine leakage occur during ablation procedures.

Urethra catheterization prior to ablation is recommended for measuring the amount of excreted urine or detecting gross hematuria [31,33,34]. Antibiotic treatment may not be necessary when sterile techniques had been maintained during ablation [33,34].

4) Types of anesthesia
Conscious sedation or monitored anesthesia care has been frequently utilized during cryoablation given that most patients can tolerate the pain associated with the procedures [30,35]. However, general anesthesia is strongly recommended during RFA or MWA considering that these procedures evoke more severe pain [36,37]. However, the type of anesthesia should be selected based on the clinical situation. Regardless of the ablation modality used, general anesthesia is useful for patients who cannot remain in a specific position for 2 hours or more [30,32]. Furthermore, general anesthesia is mandatory when treating RCC abutting the adrenal gland or sympathetic chain due to frequent hypertensive crisis [27]. An arterial or central line should be secured prior to thermal ablation for continuous blood pressure monitoring given that intermittent blood pressure measurements can create difficulties during immediate intervention in patients with hypertensive crisis or a hypovolemic shock.

5) Preventing complications
Ureter catheterization and pyeloperfusion are recommended to reduce thermal damage to the urothelium when treating RCC close to the ureteropelvic junction [8,31,38,39]. Hydrodissection is also recommended to avoid thermal damage to the small or large bowel when the RCC-to-bowel distance is below 0.5 cm (Fig. 1) [8,31,40]. However, the safe distance should be adjusted considering that the size of the ablation area depends on the degree of tissue perfusion [41], type of thermal ablation [8,31,40,42], and neighboring organs [43]. As such, interventional oncologists should carefully monitor the growth of the ablation area during thermal ablation. Notably, the size of the ablation margins is much easier to determine with cryoablation than with RFA or MWA during CT-guided procedures.

6) Renal mass biopsy
Percutaneous biopsy is mandatory to avoid unnecessary treatment for benign tumors [8,9], including angiomyolipoma and oncocytoma, which have been histologically detected among incidental renal masses [44,45]. Moreover, determining the subtypes of RCC or metastasis can be useful for further management after thermal ablation. Therefore, thermal ablation should not be performed without histologic confirmation of RCC. Repeat biopsy is recommended in cases of non-diagnostic biopsy results [46]. US has been frequently preferred for renal mass biopsy guidance given that Asian patients tend to have lower body mass indices than Western patients [3,47,48]. However, CT is recommended for the biopsy of RCCs that are inaccessible under US guidance. Renal mass biopsy should not be performed on the same day as thermal ablation considering that precise diagnosis requires...
several days.

2. Thermal ablation

1) Types of ablations

The appropriate ablation modality is important for achieving technical success without complications. The size or location of the RCCs may influence the type of ablations selected due to differences in treatment outcomes. Accordingly, cryoablation or MWA can be useful for tumor sizes more than 3 cm given that these techniques can create a larger ablation area than RFA using a single electrode [49,50]. For RCCs located in the renal sinus, however, cryoablation is superior to RFA or MWA owing to less urothelial damage [22,51,52]. For an RCC less than 3 cm and not located in the renal sinus, no differences between ablation modalities in terms of oncologic outcomes or major complications have been noted. As such, RFA still remains a good option for treating small RCC (less than 3 cm) given its generally lower costs compared to cryoablation or MWA.

Economic status and insurance systems are important when selecting an ablation modality. For instance, RFA has been more frequently performed in Korea given its much lower costs compared to cryoablation or MWA. This may be attributed to differences in economic status between Korean and Western individuals. Moreover, the Korean government does not reimburse patients undergoing cryoablation or MWA as much as they do patients undergoing RFA. However, cryoablation has been found to be more common than RFA in Taiwan and Japan considering the sufficient reimbursements provided by their governments.

2) Guiding modalities

The choice of the guiding modality is also important for achieving successful renal tumor ablation. CT remains the
most preferred guiding modality during ablation procedures given the familiarity of interventional radiologists with CT-guided procedures [89]. Moreover, this imaging modality can clearly determine the cryoablation margin created by the ice ball during the freezing cycle. In contrast, RFA or MWA may have difficulty clearly displaying the ablation margin during the procedures, requiring greater radiologist experience during estimation. However, one considerable issue with CT guidance is the high radiation exposure of the patients [30]. As such, low-dose CT protocols are strongly recommended in Asian patients with relatively lower body mass indices [29]. Interventional oncologists need to know how to reduce the number, range, tube voltage, and tube current of CT scans [29,30].

US can be used to show or monitor the ablation margin given that the ablation area becomes echogenic during RFA or MWA. This imaging modality is useful for treating exophytic RCCs clearly seen in slim Asian patients. However, more frequent local tumor progression had been reported following US-guided ablation given that posterior US shadowing can result from an echogenic ablation area, which makes it difficult to determine whether the tumor margin and the RCC had been completely ablated [3,48]. However, local tumor progression tends to be more frequent following US-guided thermal ablation because posterior US shadowing resulting from echogenic ablation area makes it difficult to determine if the tumor margin as well as the RCC is completely ablated [36]. MRI is not commonly used for RFA guidance due to its high cost and low availability of MRI-compatible RF electrodes. RFA uses an electrical current, which can disturb the magnetic field. Accordingly, MRI is not useful for RFA guidance considering that image distortion occurs during ablation procedures. Furthermore, MRI-compatible electrodes and devices have yet to be commercially available.

3) Bosniak III or IV cysts

Considering that a higher Bosniak classification has been associated with increased incidence of RCC, surgical intervention is recommended for Bosniak III or IV cysts [53-55]. Reports have shown relatively high diagnosis rates of benign Bosniak III cysts, approximately 50% of which have been confirmed to be RCC postoperatively [56,57]. In contrast, approximately 90% of Bosniak IV cysts have been postoperatively confirmed to be RCC [55]. Although percutaneous biopsy can be performed for these cysts, poor yields have been documented [47] given that the solid component of Bosniak III and IV cysts is much smaller than similar sized solid renal masses. One study showed that the biopsy diagnosis rates for Bosniak III and IV cysts is only approximately 50% [47]. Leakage of cystic fluid may increase the risk of cancer seeding. Park et al. [58,59] reported that RFA promotes higher recurrence-free survival rates in patients with Bosniak III or IV cysts despite most of the cystic masses not having been proven to be RCCs. Cryoablation and MWA can also provide excellent treatment outcomes for these cysts (Fig. 1) [60,61]. Only a few studies have determined the long-term outcomes of thermal ablation treatment for Bosniak III or IV cysts. Considering the modest evidence level, thermal ablation should be selectively performed in patients who cannot undergo surgery.

3. Thermal ablation modalities

1) Radiofrequency ablation

RFA has been known as the first ablation modality for treating RCC. RFA delivers electrical current to the tumor tissue where it induces ionic agitation to increase the temperature over 60°C, leading to cell death [62,65].

The standard RFA protocol includes an initial electrical power of 30–40 W that is increased by 10 W per minute with 2 breaks/roll-offs during ablation [66,67]. Compared to other ablation modalities, RFA is a more well-established technique with more clinical results available for analysis; however, blood flow can limit the size of the ablation zone [68]. Given the hypervascular nature of most RCCs and the kidney, achieving complete ablation is occasionally difficult. Multipolar or multiple-electrode switching systems can be used to reinforce treatment effects [65,69].

In USA, local control rates of T1a RCCs can range from 91% to 100% [11,70-73], and are comparable to those among Asians, which can range from 95% to 100% [70,74,75]. Moreover, estimates have shown that the 5-year overall survival and cancer-specific survival rates among patients with T1 RCC can range from 72% to 97% and 96% to 97% in the USA, respectively [11,67,71,76]. On the other hand, estimates in Asian countries have found that the same survival rates can range from 78% to 90% and 96% to 100%, respectively [70,74,77].

RFA has been found to have complication rates comparable to those of partial nephrectomy, with major complication rates following RFA of T1 RCCs ranging from 0% to 13% [69,70,72,74,76,78,79]. Hemorrhage has been the most frequent complication, which is often self-limiting [67,78,80,81]. Urothelial injuries are quite not common but are more frequent compared to cryoablation, with reported incidence rate ranging from 2% to 10% [67,76,78,82].
2) Cryoablation

Cryoablation induces cell death through repeated freezing and thawing (Fig. 1). Accordingly, tumor cell injury occurs due to two physiologic events [83], namely osmotic dehydration [84] and intracellular freezing. The predominance of one type of injury mechanism over the other depends on the cooling rate, end temperature, time held at the minimum temperature, and thawing rate [85]. Cryoablation sessions consist of double freeze-thaw cycles involving 10 to 15 minutes of freezing and 8 to 10 minutes of thawing. The double freeze cycle produces significantly larger areas of necrosis than single freezing, regardless of the thaw process [86].

Cryoablation has several advantages over RFA or MWA. First, cryoablation has been associated with more tolerable pain and lesser urothelium damage [22,51,52]. Second, cryoablation promotes fewer incidences of ureter obstruction or urine leakage compared to the other modalities when treating central RCCs. Third, the cryoablation zone is much clearer on MRI and CT. Fourth, applying multiple probes simultaneously allows for greater flexibility in the shape of the isotherm. Fifth, the ability to change the approach trajectory and control the rate at which temperature changes in each individual applicator make cryoablation more feasible compared to other modalities [49].

Studies have shown that cryoablation provides excellent local control rate for T1a RCCs, with reported 5-year recurrence-free survival rates exceeding 90% [28,87,88]. Despite having higher local recurrence rates compared to surgery, cryoablation can be an alternative treatment for T1b RCCs among poor surgical candidates [13,89-91]. Bleeding or hematuria has the most common complication following cryoablation. Moreover, ureter strictures, colon perforations or fistulas, and nerve injuries have been reported, albeit rarely. Evidence has shown that the incidence of major complications is significantly associated with tumor size [14,28,87,92,93].

3) Microwave ablation

Despite having been clinically available for a shorter period of time compared to other modalities, MWA has been found to be apparently safe and effective for the management of renal tumors [94]. MWA, which induces cell death through water molecule agitation, allows for high tissue temperatures and a large ablation area over a short amount of time [95-97]. MWA is not particularly influenced by heat sink effects when treating RCCs around large vessels [95-97]. The kidney is a highly perfused organ with approximately four times the perfusion of the liver [41]. MWA can be performed simultaneously with multiple probes to ablate larger tumors [50].

The standard MWA protocol routinely used for renal tumor ablation includes setting the main frequency to 2.450 MHz, power output to 50 W for 10 minutes [98]. A single antenna can be used to treat smaller RCCs (≤3.0 cm), while and two or more antennas are used for larger ones (>3.0 cm).

A recent meta-analysis reported no difference in local recurrence and cancer-specific mortality between MWA and nephron-sparing surgery [16]. Moreover, the same study found that MWA had relatively low complication rates that were similar to those of other ablation modalities [16]. Nonetheless, further investigations are necessary to determine the long-term safety and oncological outcomes of MWA.

4. Post-ablation considerations

1) Post-ablation imaging follow-up

Appropriate follow-up is also important to determine the presence of local tumor progression. Contrast-enhanced CT or MRI has been considered the best imaging modality for assessing renal function following renal tumor ablation [15,18]. Among patients with chronic kidney disease, unenhanced MRI including diffusion-weighted imaging may be used for post-ablation assessment given the need for contrast material [15,18]. Although contrast-enhanced US can be a good option for follow-up examination, it requires a steep learning curve to obtain sufficient skill.

Unfortunately, no general consensus has been established regarding the follow-up interval. Typically, a 6-month interval is recommended until 2 years post-ablation. Thereafter, annual follow-up is recommended until 5 years post-ablation.

2) Influence on renal function

Several studies found no significant decrease in renal function following thermal ablation for sporadic RCC [28,70,74,87,88]. However, larger tumor sizes, endophytic locations, multiple tumors, and multiple sessions can result in loss of renal function [99]. Nonetheless, such conditions are present when ablating tumors with larger margin [99]. These phenomena frequently occur when treating hereditary RCCs [18,19,25] and T1b RCCs [77]. Granted that renal function was not affected by thermal ablation, patients with hereditary RCCs do not have to rely on dialysis even when all recurrent tumors are treated without local tumor progression. However, thermal ablation lengthens the dialysis-free survival period [18,99] considering that it tends to preserve renal function better compared to surgery.

CONCLUSIONS

Image-guided ablation therapy can be expected to be-
come increasingly popular among Asian countries as the necessity for minimally invasive treatments gains traction as an alternative to partial nephrectomy. Therefore, Asian interventional oncologists need to be familiar with the first version of the ACTA guidelines. For the safe and satisfactory performance of renal tumor ablation in Asian patients with RCCs, they should know pre-ablation and post-ablation considerations.

**CONFLICTS OF INTEREST**

The authors have nothing to disclose.

**AUTHORS’ CONTRIBUTIONS**

Research conception and design: Byung Kwan Park, Shu-Huei Shen, Masashi Fujimori, and Yi Wang. Data acquisition: Byung Kwan Park. Statistical analysis: Byung Kwan Park. Data analysis and interpretation: Byung Kwan Park, Shu-Huei Shen, Masashi Fujimori, and Yi Wang. Drafting of the manuscript: Byung Kwan Park, Shu-Huei Shen, Masashi Fujimori, and Yi Wang. Critical revision of the manuscript: Byung Kwan Park, Shu-Huei Shen, Masashi Fujimori, and Yi Wang. Administrative, technical, or material support: Byung Kwan Park. Supervision: Byung Kwan Park. Approval of the final manuscript: Byung Kwan Park. Statistical analysis: Byung Kwan Park. Administrative, technical, or material support: Byung Kwan Park. Approval of the final manuscript: Byung Kwan Park. Supervision: Byung Kwan Park. Approval of the final manuscript: Byung Kwan Park.

**REFERENCES**

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31.
2. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006;176(6 Pt 1):2353-8.
3. Murai M, Oya M. Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol 2004;14:229-33.
4. Han S, Wang D, Li C, Xing N, Zhang S. Analysis for the incidence trends of renal cell carcinoma in China, 1998-2008. Oncol Prog 2018;16:1234-7.
5. Liu SZ, Guo LW, Cao XQ, Chen Q, Zhang SK, Zhang M, et al. [Estimation on the incidence and mortality of kidney cancer in China, in 2014]. Zhonghua Liu Xing Bing Xue Za Zhi 2018;39:1346-50. Chinese.
6. Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, et al. Renal mass and localized renal cancer: AUA Guideline. J Urol 2017;198:520-9.
7. Ljungberg B, Albiger L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 2019;75:799-810.
8. Higgins IJ, Hong K. Renal ablation techniques: state of the art. AJR Am J Roentgenol 2015;205:735-41.
9. Krokidis ME, Orsi F, Katsanos K, Helmberger T, Adam A. CIRSE guidelines on percutaneous ablation of small renal cell carcinoma. Cardiovasc Intervent Radiol 2017;40:177-91.
10. Kim JH, Chae HW, Chin SO, Ku CR, Park KH, Lim DJ, et al. Diagnosis and treatment of growth hormone deficiency: a position statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology. Endocrinol Metab (Seoul) 2020;35:272-87.
11. Andrews JR, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, et al. Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2019;76:244-51.
12. Bhindi B, Mason RJ, Haddad MM, Boorjian SA, Leibovich BC, Atwell TD, et al. Outcomes after cryoablation versus partial nephrectomy for sporadic renal tumors in a solitary kidney: a propensity score analysis. Eur Urol 2018;73:254-9.
13. Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9.
14. Zargar H, Atwell TD, Cadeddu JA, de la Rosette JJ, Janetschek G, Kaouk JH, et al. Cryoablation for small renal masses: selection criteria, complications, and functional and oncologic results. Eur Urol 2016;69:116-28.
15. Park BK, Gong IH, Kang MY, Sung HH, Jeon HG, Jeong BC, et al. RFA versus robotic partial nephrectomy for T1a renal cell carcinoma: a propensity score-matched comparison of midterm outcome. Eur Radiol 2018;28:2979-85.
16. Uhlig J, Strauss A, Rücker G, Seif Amir Hosseini A, Lotz J, Trojan L, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. Eur Radiol 2019;29:1293-307.
17. Sung HH, Park BK, Kim CK, Choi HY, Lee HM. Comparison of percutaneous radiofrequency ablation and open partial nephrectomy for the treatment of size- and location-matched renal masses. Int J Hyperthermia 2012;28:227-34.
18. Park BK, Kim CK. Percutaneous radio frequency ablation of renal tumors in patients with von Hippel-Lindau disease: prelimiary results. J Urol 2010;183:1703-7.
19. Park BK, Kim CK, Park SY, Shen SH. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease: indications, techniques, complications, and outcomes. Acta Radiol 2013;54:418-27.
20. Xiaobing W, Wentao G, Guangxiang L, Fan Z, Weidong G, Hongqian G, et al. Comparison of radiofrequency ablation and
partial nephrectomy for tumor in a solitary kidney. BMC Urol 2017;17:79.
21. Lin Y, Liang P, Yu XL, Yu J, Cheng ZG, Han ZY, et al. Percutaneous microwave ablation of renal cell carcinoma is safe in patients with a solitary kidney. Urology 2014;83:357-63.
22. Rosenberg MD, Kim CY, Tsivian M, Suberlak MN, S dopo DR, Polascik TJ, et al. Percutaneous cryoablation of renal lesions with radiographic iceball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. AJR Am J Roentgenol 2011;196:935-9.
23. Maciolek KA, Abel EJ, P osielski NM, Hinshaw JL, Lubner MG, Lee FT Jr, et al. Tumor location does not impact oncologic outcomes for percutaneous microwave ablation of clinical T1a renal cell carcinoma. Eur Radiol 2019;29:6319-29.
24. Hudspeth TN, Abdelsalam ME, Sabir SH, Kusin SB, Matin SF, Wood CG, et al. Minimally invasive image guided thermal ablation for recurrent renal cell carcinoma (RCC) after ipsilateral partial nephrectomy. J Clin Oncol 2018;36(15 Suppl):e16557.
25. Park SY, Park BK, Kim CK, Lee HM, Jeon SS, Seo SI, et al. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease previously undergoing a radical nephrectomy or repeated nephron-sparing surgery. Acta Radiol 2011;52:680-5.
26. Oh k hunov Z, Chamberlin J, Moreira DM, George A, Babaian K, Shah P, et al. Salvage percutaneous cryoablation for locally recurrent renal-cell carcinoma after primary cryoablation. J Endourol 2016;30:632-7.
27. Uppot RN, Gervais DA. Imaging-guided adrenal tumor ablation. AJR Am J Roentgenol 2013;200:1226-33.
28. Georgiades CS, Hong K, Bizzell C, Geschwind JF, Rodriguez R. Safety and efficacy of CT-guided percutaneous cryoablation for renal cell carcinoma. J Vasc Interv Radiol 2008;19:1302-10.
29. Park BK. Low-dose CT protocols for guiding radiofrequency ablation for the treatment of small renal cell carcinomas. Int J Hyperthermia 2018;34:877-82.
30. Park BK, Morrison PR, Tatl i S, Govindarajulu U, Tuncali K, Judy P, et al. Estimated effective dose of CT-guided percutaneous cryoablation of liver tumors. Eur J Radiol 2012;81:1702-6.
31. Park BK, Kim CK. Complications of image-guided radiofrequency ablation of renal cell carcinoma: causes, imaging features and prevention methods. Eur Radiol 2009;19:2180-90.
32. Kim HJ, Park BK, Chung IS. Comparison of general anesthesia and conscious sedation during computed tomography-guided radiofrequency ablation of T1a renal cell carcinoma. Can Assoc Radiol J 2018;69:24-9.
33. Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Muller PR. Radiofrequency ablation of renal cell carcinoma: part 2. Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol 2005;185:72-80.
34. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: part 1. Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005;185:64-71.
35. Ok hunov Z, Juncal S, Ordon M, George AK, Lusch A, del Junco M, et al. Comparison of outcomes in patients undergoing percutaneous renal cryoablation with sedation vs general anesthesia. Urology 2015;85:130-4.
36. Park BK, Kim CK, Choi HY, Lee HM, Jeon SS, Seo SI, et al. Limitation for performing ultrasound-guided radiofrequency ablation of small renal masses. Eur J Radiol 2010;75:248-52.
37. Chan P, Velasco S, Vessel le G, Boucebci S, Herpe G, Debaene B, et al. Percutaneous microwave ablation of renal cancers under CT guidance: safety and efficacy with a 2-year follow-up. Clin Radiol 2017;72:786-92.
38. Wah TM, Koenig P, Irving HC, Gervais DA, Mueller PR. Radiofrequency ablation of a central renal tumor: protection of the collecting system with a retrograde cold dextrose pyeloperfusion technique. J Vasc Interv Radiol 2005;16:1551-5.
39. Hwang SI, Cho JY, Kim SH, Jun SR, Lee HJ, Moon KC, et al. Protection of the renal collecting system during radiofrequency ablation with antegrade cold dextrose infusion. Radiology 2010;256:759-66.
40. Park BK, Kim SH, Byun JY, Kim YS, Kwon GY, Jang IS. CT-guided instillation of 5% dextrose in water into the anterior pararenal space before renal radiofrequency ablation in a porcine model: positive and negative effects. J Vasc Interv Radiol 2007;18:1561-9.
41. Pandharipande PV, Gervais DA, Hartman RI, Harisinghani MG, Feldman AS, Mueller PR, et al. Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis. Radiology 2010;256:836-46.
42. Shimizu K, Mogami T, Michimoto K, Kameoka Y, Tokashiki T, Kurata N, et al. Digestive tract complications of renal cryoablation. Cardiovasc Interv Radiol 2016;39:122-6.
43. Park BK, Kim CK. CT-guided radiofrequency ablation of a renal tumor abutting vascular pedicle in a patient with von Hippel Lindau disease. Cardiovasc Interv Radiol 2009;32:840-2.
44. Silverman SG, Gan YU, Mortele KJ, Tuncali K, Cibas ES. Renal masses in the adult patient: the role of percutaneous biopsy. Radiology 2006;240:6-22.
45. Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass. Radiology 2008;249:16-31.
46. Patel HD, Johnson MH, Pierorazio PM, Sozio SM, Sharma R, Iyoha E, et al. Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol 2016;195:1340-7.
47. Park SY, Park BK, Kim CK, Kwon GY. Ultrasound-guided core biopsy of small renal masses: diagnostic rate and limitations. J Vasc Interv Radiol 2013;24:90-6.
48. Jih J, Mukherjea A, Vittinghoff E, Nguyen TT, Tsoh JY, Fukushima Y, et al. Using appropriate body mass index cut points for overweight and obesity among Asian Americans. Prev Med 2014;65:1-6.
49. Hegarty NJ, Gill IS, Desai MM, Remer EM, O’Malley CM, Kaukou JH. Probe-ablative nephron-sparing surgery: cryoablation versus radiofrequency ablation. Urology 2006;68(1 Suppl):7-13.
50. Laesecke PE, Lee FT Jr, Sampson LA, van der Weide DW, Brace CL. Microwave ablation versus radiofrequency ablation in the kidney: high-power triaxial antennas create larger ablation zones than similarly sized internally cooled electrodes. J Vasc Interv Radiol 2009;20:1224-9.
51. Brashears JH 3rd, Raj GV, Crisci A, Young MD, Dylewski D, Nelson R, et al. Renal cryoablation and radio frequency ablation: an evaluation of worst case scenarios in a porcine model. J Vasc Interv Radiol 2005;173:2160-5.
52. Janzen NK, Perry KT, Han KR, Kristo B, Raman S, Said JW, et al. The effects of intentional cryoablation and radio frequency ablation of renal tissue involving the collecting system in a porcine model. J Urol 2005;173:1368-74.
53. Bosniak MA. The current radiological approach to renal cysts. Radiology 1986;158:1-10.
54. Bosniak MA. Problems in the radiological diagnosis of renal parenchymal tumors. Urol Clin North Am 1993;20:217-30.
55. Silverman SG, Pedrosa I, Ellis JH, Hindman NM, Schieda N, Smith AD, et al. Bosniak classification of cystic renal masses, version 2019: an update proposal and needs assessment. Radiology 2019;292:475-88.
56. Schouts IG, Zaccai K, Hunink MG, Verhagen PCMS. Bosniak classification for complex renal cysts reevaluated: a systematic review. J Urol 2017;198:12-21.
57. Sevcenco S, Spick C, Helbich TH, Heinz G, Shariat SF, Klingler HC, et al. Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography - a systematic review and meta-analysis. Eur Radiol 2017;27:2239-47.
58. Park JJ, Park BK, Park SY, Kim CK. Percutaneous radiofrequency ablation of sporadic Bosniak III or IV lesions: treatment techniques and short-term outcomes. J Vasc Interv Radiol 2015;26:46-54.
59. Park BK, Kim CK, Lee HM. Image-guided radiofrequency ablation of Bosniak category III or IV cystic renal tumors: initial clinical experience. Eur Radiol 2008;18:1519-25.
60. Aoun HD, Littrup PJ, Jaber M, Memon F, Adam B, Krycia M, et al. Percutaneous cryoablation of renal tumors: is it time for a new paradigm shift? J Vasc Interv Radiol 2017;28:1363-70.
61. Carrafiello G, Dionigi G, Ierardi AM, Petrillo M, Fontana F, Floridi C, et al. Efficacy, safety and effectiveness of image-guided percutaneous microwave ablation in cystic renal lesions Bosniak III or IV after 24 months follow up. Int J Surg 2013;11 Suppl 1:S30-5.
62. Knavel EM, Brace CL. Tumor ablation: common modalities and general practices. Tech Vasc Interv Radiol 2013;16:192-200.
63. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014;14:199-208.
64. Nikfarjam M, Muralidharan V, Christophi C. Mechanisms of focal heat destruction of liver tumors. J Surg Res 2005;127:208-23.
65. Sommer CM, Lemm G, Hohenstein E, Stampfl U, Bellemann N, Teber D, et al. Bipolar versus multipolar radiofrequency (RF) ablation for the treatment of renal cell carcinoma: differences in technical and clinical parameters. Int J Hyperthermia 2013;29:21-9.
66. Miyazaki M, Iguchi T, Takaki H, Yamanaka T, Tamura Y, Tokue H, et al. Ablation protocols and ancillary procedures in tumor ablation therapy: consensus from Japanese experts. Jpn J Radiol 2016;34:647-56.
67. Iannuccilli JD, Dupuy DE, Beland MD, Machan JT, Golijanin DJ, Mayo-Smith WW. Effectiveness and safety of computed tomography-guided radiofrequency ablation of renal cancer: a 14-year single institution experience in 203 patients. Eur Radiol 2016;26:1656-64.
68. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009;20(7 Suppl):S377-90.
69. Takaki H, Nakatsuka A, Uraki J, Yamanaka T, Fujimori M, Hasegawa T, et al. Renal cell carcinoma: radiofrequency ablation with a multiple-electrode switching system--a phase II clinical study. Radiology 2013;267:285-92.
70. Takaki H, Yamakado K, Soga N, Arima K, Nakatsuka A, Kashima M, et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol 2010;28:460-8.
71. Owleny EO, Park SK, Tan YK, Best SL, Trimmer C, Cadeddu JA. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol 2012;61:1156-61.
72. Zhou W, Herwald SE, McCarthy C, Uppot RN, Arellano RS. Radiofrequency ablation, cryoablation, and microwave ablation for T1a renal cell carcinoma: a comparative evaluation of therapeutic and renal function outcomes. J Vasc Interv Radiol
73. Camacho JC, Kokabi N, Xing M, Master VA, Pattaras JG, Mittal PK, et al. R.E.N.A.L. (Radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines) nephrometry score predicts early tumor recurrence and complications after percutaneous ablative therapies for renal cell carcinoma: a 5-year experience. J Vasc Interf Radiol 2015;26:686-93.

74. Chang X, Liu T, Zhang F, Ji C, Zhao X, Wang W, et al. Radiofrequency ablation versus partial nephrectomy for clinical T1a renal-cell carcinoma: long-term clinical and oncologic outcomes based on a propensity score analysis. J Endourol 2015;29:518-25.

75. Kim HJ, Park BK, Park JH, Kim CK. CT-guided radiofrequency ablation of T1a renal cell carcinoma in Korea: mid-term outcomes. Korean J Radiol 2016;17:763-70.

76. Dai Y, Covarrubias D, Uppot R, Arellano RS. Image-guided percutaneous radiofrequency ablation of central renal cell carcinoma: assessment of clinical efficacy and safety in 31 tumors. J Vasc Interv Radiol 2017;28:1643-50.

77. Hasegawa T, Yamanaka T, Gobara H, Miyazaki M, Takaki H, Sato Y, et al. Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study. Jpn J Radiol 2018;36:551-8.

78. Atwell TD, Carter RE, Schmit GD, Carr CM, Boorjian SA, Curry TB, et al. Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J Vasc Interv Radiol 2012;23:48-54.

79. Mimura H, Arai Y, Yamakado K, Sone M, Takeuchi Y, Miki T, et al. Phase I/II study of radiofrequency ablation for malignant renal tumors: Japan Interventional Radiology in Oncology Study Group 0701. Cardiovasc Intervent Radiol 2016;39:717-23.

80. Zhou W, Arellano RS. Thermal ablation of T1c renal cell carcinoma: a comparative assessment of technical performance, procedural outcome, and safety of microwave ablation, radiofrequency ablation, and cryoablation. J Vasc Interv Radiol 2018;29:943-51.

81. Takaki H, Soga N, Kanda H, Nakatsuka A, Uraki J, Fujimori M, et al. Radiofrequency ablation versus radical nephrectomy: clinical outcomes for stage T1b renal cell carcinoma. Radiology 2014;270:292-9.

82. Weizer AZ, Raj GV, O’Connell M, Robertson CN, Nelson RC, Polascik TJ. Complications after percutaneous radiofrequency ablation of renal tumors. Urology 2005;66:1176-80.

83. Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology 2002;60(2 Suppl 1):40-9.

84. Mazur P. Freezing of living cells: mechanisms and implications. Am J Physiol 1984;247(3 Pt 1):C125-42.

85. Smith DJ, Fahssi WM, Swanlund DJ, Bischof JC. A parametric study of freezing injury in AT-1 rat prostate tumor cells. Cryobiology 1999;39:13-28.

86. Woolley ML, Schulsinger DA, Durand DB, Zeltser IS, Walter WC. Effect of freezing parameters (freeze cycle and thaw process) on tissue destruction following renal cryoablation. J Endourol 2002;16:519-22.

87. Atwell TD, Schmit GD, Boorjian SA, Mandrekar J, Kurup AN, Weisbrod AJ, et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol 2013;200:461-6.

88. Prarasteh A, Snyder L, Boncher N, Passalacqua M, Rosenblum D, Prologo JD. Cryoablation vs. radiofrequency ablation for small renal masses. Acad Radiol 2011;18:97-100.

89. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol 2008;179:1227-33; discussion 1233-4.

90. Klatte T, Grumbmüller B, Waldert M, Weibl P, Remzi M. Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies. Eur Urol 2011;60:435-43.

91. Caputo PA, Zargar H, Ramirez D, Andrade HS, Akca O, Gao T, et al. Cryoablation versus partial nephrectomy for clinical T1b renal tumors: a matched group comparative analysis. Eur Urol 2017;71:111-7.

92. Gannan J, Van Strijen MJ, Nielsen TK, King AJ, Montauban Van Swijndregt AD, Cazzato RL, et al. Safety of percutaneous renal cryoablation: an international multicentre experience from the EuRECA retrospective percutaneous database. Eur Radiol 2019;29:6293-9.

93. Schmit GD, Schenck LA, Thompson RH, Boorjian SA, Kurup AN, Weisbrod AJ, et al. Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology 2014;272:903-10.

94. Clark PE, Woodruff RD, Zagoria RJ, Hall MC. Microwave ablation of renal parenchymal tumors before nephrectomy: phase I study. AJR Am J Roentgenol 2007;188:1212-4.

95. Sommer CM, Sommer SA, Mokry T, Gockner T, Gnutzmann D, Bellemann N, et al. Quantification of tissue shrinkage and dehydration caused by microwave ablation: experimental study in kidneys for the estimation of effective coagulation volume. J Vasc Interv Radiol 2013;24:1241-8.

96. Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol 2009;38:135-43.

97. Yu J, Liang P, Yu X, Liu F, Chen L, Wang Y. A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: results in ex vivo and in vivo
porcine livers. Eur J Radiol 2011;79:124-30.

98. Yu J, Liang P, Yu XL, Cheng ZG, Han ZY, Zhang X, et al. US-guided percutaneous microwave ablation versus open radical nephrectomy for small renal cell carcinoma: intermediate-term results. Radiology 2014;270:880-7.

99. Park SY, Park BK, Kim CK. Thermal ablation in renal cell carcinoma: what affects renal function? Int J Hyperthermia 2012;28:729-34.